SCHEMBL10080320

SCHEMBL10080320

BCC(=O)c1cccc(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.57
CA2 P00918 2/20 0.57
CA9 Q16790 2/20 0.57
CA1 P00915 1/20 0.57
CA6 P23280 1/20 0.57
PARP1 P09874 1/20 0.55
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 2/20 0.55
EGLN2 Q96KS0 1/20 0.52
CTNNB1 P35222 1/20 0.49
FASN P49327 1/20 0.48
CLK1 P49759 1/20 0.47
DYRK1A Q13627 1/20 0.47
DYRK1B Q9Y463 1/20 0.47
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
CA5A P35218 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30497947 0.81 CA12 (0.59) CA12CA2CA9CA1CA6
SCHEMBL108054 0.81 CA12 (0.59) CA12CA2CA9CA1CA6
SCHEMBL30517873 0.79 GSK3B (0.59) CA12CA2CA9CA1CA6
SCHEMBL13305139 0.79 CA12 (0.57) CA12CA2CA9CA1CA6
SCHEMBL30408859 0.79 ALDH1A1 (0.59) CA12CA2CA9CA1CA6
SCHEMBL1361623 0.79 GSK3B (0.59) CA12CA2CA9CA1CA6
SCHEMBL2178782 0.79 PARP1 (0.61) CA12CA2CA9CA1CA6
SCHEMBL620024 0.79 ALDH1A1 (0.59) CA12CA2CA9CA1CA6
SCHEMBL79656 0.79 CA12 (0.57) CA12CA2CA9CA1CA6
SCHEMBL6398443 0.79 CA12 (0.57) CA12CA2CA9CA1CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8303935-B2 Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-11-06 US disclosed
US-20120271053-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-10-25 US disclosed
US-8207189-B2 Compound having affinity for amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-06-26 US disclosed
US-20100069640-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID NIHON MEDI-PHYSICS COL, LTD. (JP) 2010-03-18 US disclosed
WO-2010011964-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069640-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID APP, APBA1, C1QBP CA12 357/4885CA2 662/4885CA9 830/4885
US-20120271053-A1 NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID APBA1, SAAL1, SLC43A1 CA12 1940/4885CA2 2231/4885CA9 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.